ABBV - Abbvie Inc

219.76
-1.690   -0.769%

Share volume: 4,399,354
Last Updated: 03-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$221.45
-1.69
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
58%
Profitability 59%
Dept financing 50%
Liquidity 38%
Performance 65%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.04%
1 Month
-3.92%
3 Months
-1.37%
6 Months
-1.00%
1 Year
2.76%
2 Year
23.12%
Key data
Stock price
$219.76
P/E Ratio 
94.80
DAY RANGE
$219.76 - $223.28
EPS 
$2.37
52 WEEK RANGE
$164.39 - $244.81
52 WEEK CHANGE
$3.54
MARKET CAP 
400.607 B
YIELD 
2.89%
SHARES OUTSTANDING 
1.768 B
DIVIDEND
$1.64
EX-DIVIDEND DATE
10-15-2025
NEXT EARNINGS DATE
07-24-2025
BETA 
0.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,908,254
AVERAGE 30 VOLUME 
$6,215,268
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Recent news